Advertisement


Ruth O'Regan, MD, on Locally Advanced and Metastatic Breast Cancer: Results of the BELLE-3 Trial

2016 San Antonio Breast Cancer Symposium

Advertisement

Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-positive, aromatase inhibitor–treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor–based treatment (Abstract S4-07).



Related Videos

Breast Cancer
Symptom Management

Patricia A. Ganz, MD: Aromatase Inhibitors Data Review

Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and aromatase inhibitors’ effect on endothelial function and heart disease (Abstracts S5-06 and S5-07).

Breast Cancer
Survivorship

Dawn Hershman, MD, on Breast Cancer Survivorship: Poster Discussion

Dawn Hershman, MD, of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, reviews findings on survivorship care plans, interventions to reduce chemotherapy-induced peripheral neuropathy, and the cardiac effects of aromatase inhibitors (Poster Discussion 4).

Breast Cancer
Genomics/Genetics

Nikhil Wagle, MD, on Breast Cancer: Advances in Genomics

Nikhil Wagle, MD, Dana-Farber Cancer Institute, discusses the genomic sequencing of ER-positive metastatic breast cancer that has become resistant to therapies and the implications for the choice of next therapy, clinical trial eligibility, and novel drug targets (Abstract S1-01).

Breast Cancer

Hyo Sook Han, MD, on Metastatic Breast Cancer: Trial Results on Veliparib, Carboplatin, and Paclitaxel

Hyo Sook Han, MD, of Moffitt Cancer Center, discusses phase II study findings on the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel vs placebo in patients with BRCA1 or BRCA2 mutations and metastatic breast cancer (Abstract S2-05).

Breast Cancer

Lisa A. Carey, MD, and Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Treatment Challenges

Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant systemic treatment in the triple-negative disease setting.

Advertisement

Advertisement




Advertisement